Geoffrey Owen Littlejohn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6174114/publications.pdf

Version: 2024-02-01

82 papers 3,375 citations

147566 31 h-index 56 g-index

84 all docs 84 docs citations

84 times ranked 3019 citing authors

#	Article	IF	CITATIONS
1	Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia. Clinical Rheumatology, 2022, 41, 53-62.	1.0	7
2	Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL dataset. Clinical Rheumatology, 2022, 41, 1105-1114.	1.0	5
3	Pharmacological Treatment of Fibromyalgia. , 2021, , 33-52.		3
4	Fibromyalgia and psoriatic arthritis: Partners together. International Journal of Rheumatic Diseases, 2021, 24, 141-143.	0.9	1
5	Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis. European Journal of Rheumatology, 2021, 8, 67-72.	1.3	4
6	Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet, The, 2021, 397, 2098-2110.	6.3	440
7	Central sensitivity and fibromyalgia. Internal Medicine Journal, 2021, 51, 1990-1998.	0.5	14
8	Key Milestones Contributing to the Understanding of the Mechanisms Underlying Fibromyalgia. Biomedicines, 2020, 8, 223.	1.4	21
9	Dynamic CTA and MRA in a case of severe Raynaud's phenomenon. Clinical Imaging, 2020, 66, 133-136.	0.8	O
10	Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia. Clinical Rheumatology, 2020, 39, 2545-2551.	1.0	21
11	Chronic pain syndromes: overlapping phenotypes with common mechanisms. F1000Research, 2019, 8, 255.	0.8	7
12	Neurogenic inflammation in fibromyalgia. Seminars in Immunopathology, 2018, 40, 291-300.	2.8	86
13	Evidence for the improvement of fatigue in fibromyalgia: A 4â€week left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation randomizedâ€controlled trial. European Journal of Pain, 2018, 22, 1255-1267.	1.4	37
14	Fibromyalgia remains a significant burden in rheumatoid arthritis patients in Australia. International Journal of Rheumatic Diseases, 2018, 21, 639-646.	0.9	37
15	Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL. Internal Medicine Journal, 2018, 48, 1185-1192.	0.5	O
16	Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the <scp>PREDICT</scp> study. International Journal of Rheumatic Diseases, 2017, 20, 460-468.	0.9	17
17	Modulation of NMDA Receptor Activity in Fibromyalgia. Biomedicines, 2017, 5, 15.	1.4	32
18	The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice. International Journal of Rheumatology, 2017, 2017, 1-8.	0.9	6

#	Article	IF	Citations
19	Fibromyalgia onset has a high impact on work ability in Australians. Internal Medicine Journal, 2016, 46, 1069-1074.	0.5	20
20	Neuroinflammation in fibromyalgia and CRPS: top-down or bottom-up?. Nature Reviews Rheumatology, 2016, 12, 242-242.	3.5	5
21	Psychological factors mediate key symptoms of fibromyalgia through their influence on stress. Clinical Rheumatology, 2016, 35, 2353-2357.	1.0	29
22	Is there a role for opioids in the treatment of fibromyalgia?. Pain Management, 2016, 6, 347-355.	0.7	16
23	International travel in the immunocompromised patient: a cross-sectional survey of travel advice in 254 consecutive patients. Internal Medicine Journal, 2015, 45, 618-623.	0.5	23
24	Fibromyalgia. Nature Reviews Disease Primers, 2015, 1, 15022.	18.1	308
25	Terminology, criteria, and definitions in complex regional pain syndrome: challenges and solutions. Journal of Pain Research, 2015, 8, 871.	0.8	17
26	Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome. Nature Reviews Rheumatology, 2015, 11, 639-648.	3.5	118
27	Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational Study. Journal of Rheumatology, 2015, 42, 1603-1609.	1.0	12
28	Rumination modulates stress and other psychological processes in fibromyalgia. European Journal of Rheumatology, 2015, 2, 143-148.	1.3	13
29	Whiplash: Same Elephant, Different Room. Journal of Rheumatology, 2014, 41, 411-413.	1.0	6
30	Complex regional pain syndrome. Rheumatology, 2014, 53, 1157-1158.	0.9	2
31	Drs. Littlejohn and Guymer reply. Journal of Rheumatology, 2014, 41, 2324-2324.	1.0	1
32	Australian and New Zealand evidenceâ€based recommendations for pain management by pharmacotherapy in adult patients with inflammatory arthritis. International Journal of Rheumatic Diseases, 2014, 17, 738-748.	0.9	3
33	Barriers to Optimal Disease Control for Rheumatoid Arthritis Patients With Moderate and High Disease Activity. Arthritis Care and Research, 2014, 66, 190-196.	1.5	56
34	Honing fibromyalgia diagnosis. Nature Reviews Rheumatology, 2014, 10, 267-269.	3.5	11
35	Metabolic Factors in Diffuse Idiopathic Skeletal Hyperostosis – A Review of Clinical Data. Open Rheumatology Journal, 2014, 8, 116-128.	0.1	68
36	Bisphosphonates for early complex regional pain syndrome. Nature Reviews Rheumatology, 2013, 9, 199-200.	3.5	11

#	Article	IF	CITATIONS
37	The SMILE Study — Safety of Methotrexate in Combination with Leflunomide in Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 228-235.	1.0	41
38	A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control. International Journal of Rheumatic Diseases, 2013, 16, 532-538.	0.9	19
39	Neuroticism in Young Women with Fibromyalgia Links to Key Clinical Features. Pain Research and Treatment, 2012, 2012, 1-7.	1.7	30
40	Muscle Changes in RSI: Is the Elephant in the Room?. Journal of Musculoskeletal Pain, 2012, 20, 269-270.	0.3	1
41	Psychological control is a key modulator of fibromyalgia symptoms and comorbidities. Journal of Pain Research, 2012, 5, 463.	0.8	18
42	The use of opioids in fibromyalgia. International Journal of Rheumatic Diseases, 2011, 14, 6-11.	0.9	57
43	Management strategies for fibromyalgia. Open Access Rheumatology: Research and Reviews, 2011, 3, 47.	0.8	1
44	Targeting fibromyalgia pain: brain–spinal cord and peripheral contributions. International Journal of Clinical Rheumatology, 2011, 6, 463-474.	0.3	1
45	Diseaseâ€modifying antiâ€rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in communityâ€based practice. Internal Medicine Journal, 2011, 41, 450-455.	0.5	20
46	Fibromyalgia: current diagnosis and management. Expert Review of Clinical Immunology, 2009, 5, 181-192.	1.3	6
47	A 1-year Safety and Efficacy Study of Duloxetine in Patients With Fibromyalgia. Clinical Journal of Pain, 2009, 25, 365-375.	0.8	63
48	Regional pain syndrome: clinical characteristics, mechanisms and management. Nature Clinical Practice Rheumatology, 2007, 3, 504-511.	3.2	15
49	Measuring quality of life in rheumatic conditions. Clinical Rheumatology, 2007, 26, 671-673.	1.0	50
50	The Fibromyalgia Bladder Index. Clinical Rheumatology, 2007, 26, 2097-2103.	1.0	16
51	Fibromyalgia syndrome. Journal of Rheumatology, 2007, 34, 1415-25.	1.0	129
52	Fibromyalgia Syndrome: Which Antidepressant Drug Should We Choose. Current Pharmaceutical Design, 2006, 12, 3-9.	0.9	29
53	Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment. Internal Medicine Journal, 2004, 34, 626-638.	0.5	17
54	Models of adjustment to chronic illness: Using the example of rheumatoid arthritis. Clinical Psychology Review, 2004, 24, 461-488.	6.0	78

#	Article	IF	CITATIONS
55	Towards epidemiological criteria for soft-tissue disorders of the arm. Occupational Medicine, 2003, 53, 313-319.	0.8	38
56	Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus. Rheumatology, 1999, 38, 59-65.	0.9	35
57	Primary care and specialist management options. Best Practice and Research in Clinical Rheumatology, 1999, 13, 469-477.	1.4	5
58	The role of sex hormones in pain response. Pain, 1999, 83, 112-113.	2.0	8
59	Pregnancy outcome in systemic lupus erythematosus (SLE): a review of 54 cases. Australian and New Zealand Journal of Medicine, 1998, 28, 18-22.	0.5	34
60	Methotrexate use in systemic lupus erythematosus. Lupus, 1997, 6, 385-389.	0.8	27
61	Fibromyalgia and Disability: Report of the Moss International Working Group on Medico-Legal Aspects of Chronic Widespread Musculoskeletal Pain Complaints and Fibromyalgia. Scandinavian Journal of Rheumatology, 1995, 24, 112-118.	0.6	52
62	Reply to Dr. Starlanyl. Journal of Musculoskeletal Pain, 1994, 2, 147-149.	0.3	0
63	Fibromyalgia Syndrome and Disease Activity in Systemic Lupus Erythematosus. Lupus, 1994, 3, 187-191.	0.8	53
64	Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain, 1994, 58, 185-193.	2.0	272
65	Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis and Rheumatism, 1993, 36, 642-646.	6.7	244
66	A unique presentation of multicentric reticulohistiocytosis in pregnancy. Arthritis and Rheumatism, 1993, 36, 269-272.	6.7	25
67	Prevalence of Myofascial Pain Syndrome in Fibromyalgia Syndrome and Regional Pain Syndrome:. Journal of Musculoskeletal Pain, 1993, 1, 19-35.	0.3	38
68	Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis Annals of the Rheumatic Diseases, 1992, 51, 1318-1321.	0.5	59
69	Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger?. Postgraduate Medical Journal, 1991, 67, 632-637.	0.9	13
70	The Radiographic Changes of Scleroderma in the Hands. Journal of Medical Imaging and Radiation Oncology, 1990, 34, 53-58.	0.6	5
71	Fibrositis/Fibromyalgia Syndrome in the Workplace. Rheumatic Disease Clinics of North America, 1989, 15, 45-60.	0.8	48
72	The diagnosis and classification of scleroderma (systemic sclerosis). Postgraduate Medical Journal, 1988, 64, 121-125.	0.9	29

#	Article	IF	CITATION
73	NEUROPSYCHIATRIC MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. Australian and New Zealand Journal of Medicine, 1988, 18, 679-684.	0.5	22
74	LUPUS AND NON-LUPUS CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS. Australian and New Zealand Journal of Medicine, 1987, 17, 501-506.	0.5	37
75	What is a patient?. Medical Journal of Australia, 1986, 145, 60-60.	0.8	0
76	WEGENER'S GRANULOMATOSIS: CLINICAL FEATURES AND OUTCOME IN SEVENTEEN PATIENTS. Australian and New Zealand Journal of Medicine, 1985, 15, 241-245.	0.5	22
77	Insulin and new bone formation in diffuse idiopathic skeletal hyperostosis. Clinical Rheumatology, 1985, 4, 294-300.	1.0	63
78	Clinical evaluation of intraâ€articular injections for lumbar facet joint pain. Medical Journal of Australia, 1985, 143, 563-565.	0.8	64
79	The use of unproven remedies for rheumatoid arthritis in Australia. Medical Journal of Australia, 1985, 143, 516-518.	0.8	38
80	Diffuse idiopathic skeletal hyperostosis and new bone formation in male gouty subjects. Rheumatology International, 1982, 2, 83-86.	1.5	36
81	Radiographic features of the hand in diffuse idiopathic skeletal hyperostosis (DISH): comparison with normal subjects and acromegalic patients Radiology, 1981, 140, 623-629.	3.6	39
82	The Effects of Dietary Fibre on Glucose Tolerance in Healthy Males. Australian and New Zealand Journal of Medicine, 1979, 9, 154-158.	0.5	21